NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 319 filers reported holding NOVOCURE LTD in Q3 2021. The put-call ratio across all filers is 1.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,818,151 | -72.1% | 112,579 | -28.4% | 0.00% | -66.7% |
Q2 2023 | $6,527,867 | -32.7% | 157,298 | -2.5% | 0.01% | -35.7% |
Q1 2023 | $9,701,905 | -18.8% | 161,322 | -0.9% | 0.01% | -26.3% |
Q4 2022 | $11,945,708 | -1.7% | 162,859 | +1.8% | 0.02% | -9.5% |
Q3 2022 | $12,155,000 | +8.1% | 159,982 | -1.1% | 0.02% | +16.7% |
Q2 2022 | $11,240,000 | -15.6% | 161,733 | +0.7% | 0.02% | 0.0% |
Q1 2022 | $13,313,000 | +3.8% | 160,685 | -6.0% | 0.02% | +20.0% |
Q4 2021 | $12,828,000 | -35.7% | 170,861 | -0.5% | 0.02% | -42.3% |
Q3 2021 | $19,939,000 | -51.2% | 171,634 | -6.9% | 0.03% | -49.0% |
Q2 2021 | $40,879,000 | +62.5% | 184,291 | -3.2% | 0.05% | +54.5% |
Q1 2021 | $25,157,000 | -23.6% | 190,326 | +0.1% | 0.03% | -28.3% |
Q4 2020 | $32,910,000 | +68.6% | 190,186 | +8.5% | 0.05% | +48.4% |
Q3 2020 | $19,519,000 | +92.3% | 175,358 | +2.5% | 0.03% | +72.2% |
Q2 2020 | $10,148,000 | +14.1% | 171,125 | +29.6% | 0.02% | -5.3% |
Q1 2020 | $8,892,000 | -20.5% | 132,039 | -0.5% | 0.02% | 0.0% |
Q4 2019 | $11,182,000 | +10.5% | 132,693 | -2.0% | 0.02% | -5.0% |
Q3 2019 | $10,123,000 | +22.7% | 135,373 | +3.8% | 0.02% | +25.0% |
Q2 2019 | $8,250,000 | +52.0% | 130,473 | +15.8% | 0.02% | +45.5% |
Q1 2019 | $5,428,000 | +40.7% | 112,682 | -2.2% | 0.01% | +22.2% |
Q4 2018 | $3,859,000 | -34.6% | 115,267 | +2.4% | 0.01% | -18.2% |
Q3 2018 | $5,900,000 | +71.4% | 112,590 | +2.4% | 0.01% | +57.1% |
Q2 2018 | $3,442,000 | +77.1% | 109,957 | +23.3% | 0.01% | +75.0% |
Q1 2018 | $1,944,000 | +5.7% | 89,173 | -2.1% | 0.00% | 0.0% |
Q4 2017 | $1,839,000 | +0.2% | 91,046 | -1.5% | 0.00% | 0.0% |
Q3 2017 | $1,836,000 | +3.7% | 92,469 | -9.6% | 0.00% | 0.0% |
Q2 2017 | $1,770,000 | +119.1% | 102,309 | +2.6% | 0.00% | +100.0% |
Q1 2017 | $808,000 | -1.2% | 99,709 | -4.3% | 0.00% | 0.0% |
Q4 2016 | $818,000 | -10.6% | 104,209 | -2.7% | 0.00% | 0.0% |
Q3 2016 | $915,000 | -26.2% | 107,109 | +0.8% | 0.00% | -33.3% |
Q2 2016 | $1,239,000 | +371.1% | 106,209 | +484.2% | 0.00% | +200.0% |
Q1 2016 | $263,000 | -24.9% | 18,179 | +16.2% | 0.00% | 0.0% |
Q4 2015 | $350,000 | – | 15,650 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |